Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
Alex A. Adjei
No relevant relationships to disclose
Patricia LoRusso
Consultant or Advisory Role - Millennium
Research Funding - Millennium
Antoni Ribas
Consultant or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Merck; Millennium; Novartis
Stock Ownership - Kite Pharma
Honoraria - Millennium
Jeffrey Alan Sosman
Consultant or Advisory Role - Millennium
Honoraria - Millennium
Anna C. Pavlick
No relevant relationships to disclose
Grace K. Dy
No relevant relationships to disclose
Xiaofei Zhou
Employment or Leadership Position - Millennium
Esha A. Gangolli
Employment or Leadership Position - Millennium
Stock Ownership - Novartis; Takeda
Russell M Walker
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Michelle Kneissl
Employment or Leadership Position - Millennium
Stephanie Faucette
Employment or Leadership Position - Millennium
Rachel Neuwirth
Employment or Leadership Position - Millennium
Viviana Bozon
Employment or Leadership Position - Millennium